These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
515 related articles for article (PubMed ID: 19325493)
21. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029 [TBL] [Abstract][Full Text] [Related]
22. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Schröder FH; Roobol MJ Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695 [TBL] [Abstract][Full Text] [Related]
24. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451 [TBL] [Abstract][Full Text] [Related]
26. [The search for better markers for prostate cancer than prostate-specific antigen]. Schenk-Braat EA; Bangma CH Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452 [TBL] [Abstract][Full Text] [Related]
27. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). Kirby RS; Fitzpatrick JM; Irani J BJU Int; 2009 Feb; 103(4):441-5. PubMed ID: 19154510 [TBL] [Abstract][Full Text] [Related]
28. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685 [TBL] [Abstract][Full Text] [Related]
29. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691 [TBL] [Abstract][Full Text] [Related]
30. A framework for the identification of men at increased risk for prostate cancer. Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625 [TBL] [Abstract][Full Text] [Related]
31. Blood biomarkers for prostate cancer detection and prognosis. Shariat SF; Karam JA; Roehrborn CG Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720 [TBL] [Abstract][Full Text] [Related]
32. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907 [TBL] [Abstract][Full Text] [Related]
33. Beyond PSA: are new prostate cancer biomarkers of potential value to New Zealand doctors? Ng L; Karunasinghe N; Benjamin CS; Ferguson LR N Z Med J; 2012 Apr; 125(1353):59-86. PubMed ID: 22522272 [TBL] [Abstract][Full Text] [Related]
34. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. Shariat SF; Karam JA; Margulis V; Karakiewicz PI BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930 [TBL] [Abstract][Full Text] [Related]
35. Quadriplex model enhances urine-based detection of prostate cancer. Jamaspishvili T; Kral M; Khomeriki I; Vyhnankova V; Mgebrishvili G; Student V; Kolar Z; Bouchal J Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):354-60. PubMed ID: 21788966 [TBL] [Abstract][Full Text] [Related]
36. Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Schellhammer PF; Wright GL Urol Clin North Am; 1993 Nov; 20(4):597-606. PubMed ID: 7505967 [TBL] [Abstract][Full Text] [Related]
37. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176 [TBL] [Abstract][Full Text] [Related]
38. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment. Hedestig O; Sandman PO; Widmark A; Rasmussen BH Scand J Urol Nephrol; 2008; 42(2):101-9. PubMed ID: 17907052 [TBL] [Abstract][Full Text] [Related]
39. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145 [TBL] [Abstract][Full Text] [Related]
40. [Prostatic specific antigen: role and significance in urologic practice]. Manolović D; Pejcić T; Milović N Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]